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Abstract 
Pyoderma gangrenosum (PG) is a distinctive ulcerative skin disorder of unknown etiology, associated with 
an underlying systemic disease in up to 70% of cases. The condition is characterized by the appearance of one or more 
necrotic ulcers with a ragged undermined violaceous border and surrounding erythema. Lesions are often initiated by 
minor trauma. The condition can affect any anatomical site, however the head and neck are rarely involved. Although 
the oral cavity is subject to recurrent minor trauma through everyday activities such as mastication and oral hygiene, 
as well as during dental treatment, oral lesions appear to be extremely rare. In an effort to provide a detailed 
explanation of the oral manifestations of PG, a systematic search was conducted using medical databases. A total of 
20 cases of PG with oral involvement were reported in the English and French literature. The objectives of this article 
are to present the pertinent diagnostic criteria and to discuss the differential diagnosis and therapeutic modalities. 
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 Pyoderma gangrenosum (PG) is a rare neutrophilic dermatosis that can involve the skin and mucosae. Sites 
of predilection are the lower extremities and the trunk, but any cutaneous site may be affected [1-3]. The skin over the 
tibia is a classic site for PG lesions. Skin lesions consist of extensive, rapidly progressing, painful necrolytic ulcers 
that can exceed 10 cm in diameter, with undermined edges and violaceous borders. Pustules or tender erythematous 
nodules can precede these ulcers. Lesions have a rapid onset and generally develop over a period of 4 to 8 weeks [4, 
5]. Cribriform scarring is a typical presentation of healed skin lesions [2, 6]. Bullous and vegetative forms have been 
reported, but are less common than the ulcerative and pustular forms [7]. The diagnosis is established between 30 and 
50 years of age. Women are more commonly affected than men. In as many as 70% of patients, an underlying systemic 
condition can be associated with the occurrence of PG [2].  
 Etiology and pathogenesis are unclear. A multifactorial origin including neutrophilic dysfunction, 
overexpression of mediators of inflammation and genetic mutations predisposing patients to PG has been suggested 
in a recent review [8, 9]. Pathergy, a skin reaction in which minor mechanical trauma such as a scratch, incision or 
needle stick leads to the development of a papule, pustule or ulceration, has been seen in about 30% of patients with 
cutaneous PG [10]. Minor trauma and surgery (colostomy, hysterectomy, caesarian section, breast surgery, etc.) are 
suggested as initiating factors in lesion development [1-4, 8, 11]. Consequently, aggressive surgical wound 
debridement or skin grafting is contra-indicated in these patients.  
 Although the oral mucosa is repeatedly traumatized through everyday activities such as mastication and 
oral hygiene, and can be iatrogenically injured during dental treatment procedures, oral manifestations of PG have 
been reported rarely and mainly as isolated cases in the scientific literature. This paucity of identified cases suggests 
that many cases may have been undiagnosed or misdiagnosed (Fig. 1). For a dental practitioner treating a patient 
known to have PG, the risk of triggering oral lesions of PG secondary to mucosal injury is unknown. Furthermore, if 
oral PG lesions were to develop, they would need to be accurately differentiated from other oral ulcerative conditions, 
such as major aphthae, traumatic ulcerative granuloma with stromal eosinophilia (TUGSE), neutropenic ulcers, 
manifestations of infectious diseases or oral squamous cell carcinoma, amongst others, in order to be properly 
managed. In an effort to provide a detailed explanation of the oral manifestations of PG, a systematic search was 
conducted using medical databases. This article presents the pertinent diagnostic criteria, discusses the differential 




































































 A thorough search using the PubMed and Embase databases was executed between September 1st 2015 and 
February 5th 2016.  The combination of MeSh terms “Oral” and “Pyoderma Gangrenosum” was entered in the search 
fields. The reference list of each article was searched for any prior unidentified cases. Considering the rare occurrence 
of oral lesions in patients diagnosed with PG, it was impossible to assess articles based on methods of randomization, 
patient selection, or blinding. No limitations on language or date of publication were imposed. None of the articles 
included in this review revealed any source of bias or conflict of interest. The quality of articles was assessed based 
on the rigor of the diagnostic methods, histopathological analysis of biopsied specimens, detailed therapeutic 
management, and patient follow-up. Only lesions clinically resembling PG and properly diagnosed by methods of 
exclusion were included in the qualitative analysis. Considering the non-specificity of the histopathologic appearance 
of these lesions, the absence of biopsies of oral ulcers was not considered as a criterion of exclusion in this review. 
However, it was considered an element reinforcing the diagnosis of PG by excluding certain similar pathologies [2]. 
Based upon these requirements, 10 cases were excluded from this review [6, 12-15]. The following Prisma Flow Chart 
exhibits the selection methodology (Fig. 2). 
  
Results  
A review of the English and French-language literature revealed 20 acceptable cases of intraoral PG. The 
important features of these cases, as reported in individual case reports, are summarized in Table 1. The clinical and 
epidemiological data is summarized in Table 2. 
 
Discussion 
Oral Manifestations of PG  
Epidemiological data was available for all patients with intraoral PG. The average age was 48.7 years (+/- 
21.86 years). Men were affected more frequently than women, with 65% (13/20) of reported intraoral PG cases 
affecting males. Oral lesions were reported in the absence of concomitant cutaneous involvement in 20.0 % (4/20) of 
cases [14, 16-18]. The most frequent sites were the tongue, buccal mucosa and soft palate, together representing 67.6% 
(23/34) of all reported oral lesions. Other lesions involved the hard palate, oropharynx, lip, commissure, gingiva, and 



































































measuring between 1 and 5 cm in greatest diameter [5, 14, 18, 21-27]. As with skin lesions, the onset is rapid and 
ulcers develop over the course of 4 to 8 weeks [12, 14]. Initially, red colored nodules or papulo-pustules can develop. 
As they rupture, irregularly shaped, painful ulcerations are created. Ulcers present irregular, rolled-out margins and a 
necrotic, grey or tan colored base. The base of the lesion can be granular and friable leading to frequent bleeding [14]. 
The edges can be elevated and PG ulcers are often bordered by an erythematous or violaceous halo underlining the 
inflammatory nature of these lesions [21, 28]. Certain ulcers are covered by an overlying yellow pseudomembrane, 
and may express purulent discharge [21, 24, 29]. Lesions on the lips can exhibit crusting [16, 29]. Supplementary 
images of oral PG ulcers showing the variety of morphologic features can be visualized in the case reports [5, 10, 20-
23, 29]. Oral and skin lesions in PG are non-indurated. They can be tender to palpation. Pain, dysphagia, sore throat 
and difficulty in movement are frequently reported complaints with oral PG. In more extensive cases, bone loss and 
destruction of the periodontal support of adjacent teeth have been reported [14, 24].  
 
 Histopathology 
 Biopsies of oral PG show non-specific histopathological features. Diagnosis is therefore based on the 
clinical features and exclusion of other causes of oral ulceration. In a case series involving 16 patients with cutaneous 
PG, 83 % of cases were diagnosed based on the clinical features and the exclusion of infectious and neoplastic causes 
[4]. Reports of extensive ulceration bordered by an overlying fibrinopurulent membrane with heavy neutrophilic 
infiltration of the lamina propria are consistently seen in  biopsied cases [5, 12, 16, 18, 23, 24, 26, 29-32]. Neutrophils 
can have an altered appearance [20]. A mixed inflammatory cell infiltrate comprised of polymorphonuclear 
neutrophils, lymphocytes, histiocytes, and plasma cells is also reported. Infiltration of lymphocytes can extend into 
the underlying skeletal muscle [26]. Granulation tissue can be identified when chronic inflammation is present. 
Vasculitis was observed in one biopsied specimen [10]. However, it is suggested that the presence of vasculitis is 
secondary to heavy inflammation and is not a direct consequence of PG [8]. Perivascular hyalinization, fibrin 
deposition, hemorrhage and leukocytoclasia can be present in some lesions [12]. 
 Almost half of microbiological cultures obtained from cutaneous and mucosal ulcers associated with PG 
are negative for infectious agents [3, 17]. However, secondary infections are common; therefore, a positive culture 
cannot exclude PG. Immunofluorescence analysis is inconclusive, and does not constitute a useful diagnostic test due 



































































Underlying systemic diseases associated with PG 
 75% (16/20) of patients with oral PG have an underlying systemic disease. Most of these cases (6/16) were 
associated with inflammatory bowel disease (IBD). In fact, PG is an extra-intestinal manifestation in up to 1% of 
patients with IBD [1]. Other underlying systemic conditions include rheumatoid arthritis, monoclonal gammopathy, 
myeloproliferative conditions, and other hematological disorders [1, 9, 33-35].  
 Some cases of cutaneous PG, sometimes accompanied by oral lesions, have been observed in patients with 
chronic hepatitis [36], acute or chronic leukemia [2, 8, 9, 33, 35], polycythemia rubra vera [10, 25] and refractory 
anemia [17]. PG was the initial manifestation of leukemia in some cases [35]. Furthermore, in 10 to 20 % of cases, an 
association with paraproteinaemia was identified [3, 5, 30].  
 Recently, PG has been included in two distinct auto-inflammatory syndromes, PAPA and PASH [37]. 
PAPA syndrome results from mutations in the proline-serine-threonine-phosphatase interactive protein 1 (PSTPIP1) 
and CD2-binding protein 1 (CD2BP1) genes, which cause a triad of pyogenic arthritis, PG and acne [35, 38]. The 
PASH triad is composed of PG, acne, and suppurative hidradenitis. Recent studies have revealed a heterozygous 
missense mutation for c.1213 C>T in the PSTPIP1 gene and an increased number of repetitions of the CCTG 
microsatellite motif in the in the promoter region of this gene in patients with PASH syndrome [37, 39]. Marzano et 
al. also reported a p.E277D missense mutation of the PSTPIP1 gene in a patient with PA-PASH syndrome (associated 
pyogenic arthritis) [40]. To date, oral PG lesions have not been reported in the context of theses syndromes. 
 Although there is no specific diagnostic test for PG, some non-specific markers of inflammation have been 
found to be elevated in affected patients. Elevated erythrocyte sedimentation rate (ESR) [5, 17, 27, 29] and C-reactive 
protein [20-22, 30] have been observed in cases of oral PG. Blood work can be useful to exclude infectious causes 
and sexually transmitted diseases (ex.: syphilis, herpes, etc.) and to investigate for hematological disorders such as 
leukemia, myelodysplastic syndromes and refractory anemia with ringed sideroblasts [17]. Autoimmune pathologies 
can be investigated using serological studies and other pertinent diagnostic tests. 
 
Differential diagnosis  
Oral PG can resemble many different entities such as mucosal tuberculosis, oral manifestations of Crohn’s 
disease, granulomatosis with polyangiitis, oral squamous cell carcinoma, necrotizing sialometaplasia, oral 



































































syphilis, neutropenic ulcers, recurrent major aphthous ulcers, and deep fungal infections (histoplasmosis, 
mucormycosis, cryptococcosis, blastomycosis). The characteristic features of these conditions are detailed in Table 3 
[41-45]. The diagnosis of PG is primarily based on recognition of the characteristic morphology and evolution of the 
lesion, the presence of an underlying systemic disease (if any) and, the exclusion of other disease processes using 
proper diagnostic tools. Although histopathological features of oral PG are non-specific, they can be useful for 
excluding other pathological conditions with a similar clinical appearance.  
Other neutrophilic dermatoses such as Behçet’s disease and Sweet’s Syndrome (SS or acute febrile 
neutrophilic dermatosis) should also be investigated. SS has a distinct clinical presentation that allows differentiating 
it from PG. Patients are febrile and present erythematous well-defined and asymmetrical plaques or papules on the 
skin [46]. Histopathology shows absence of vasculitis, a diffuse perivascular and nodular neutrophilic infiltrate, and 
various degrees of edema [46, 47] . Mucosal involvement is rare. The diagnosis of Behçet’s disease is based on the 
identification of one major (2 points) and two minor (1 point each) criteria as suggested by the International Criteria 
for Behçet’s disease for a total score of 4 and over [48]. Major criteria include recurrent oral aphthous ulcerations, 
while minor criteria include recurrent aphthous-like genital ulcers, uveitis, retinal vasculitis, and cutaneous lesions 
such as erythema nodosum, pseudofolliculitis, papulopustular lesions or a positive pathergy test.  
The controversial term Malignant Pyoderma (MP) should be avoided in cases of aggressive oral PG. Revised 
cases of MP have been identified as granulomatosis with polyangiitis [7, 49]. 
 
 Treatment of oral lesions   
 Treatment of the underlying systemic condition, if any, represents an integral part in the management of 
oral and skin lesions of PG. Systemic corticosteroids are most commonly used and constitute the first line of 
immunosuppressive therapy. Oral prednisone, prednisolone (0.5-1 mg/kg/day) and IV methylprednisolone (0.5–1 
mg/kg/day) are all effective in treating both oral and cutaneous PG  [25, 50, 51]. For the treatment of oral PG, lower 
dosages of corticosteroids have been effective in treating lesions and preventing relapses [14, 19, 24, 30, 52]. 
Intralesional triamcinolone injections can complement oral steroids or immunomodulatory drugs [18, 53]. 
Immunosuppressive agents such as cyclosporine A (5 mg/kg/day), tacrolimus, azathioprine, and cyclophosphamide 
have also been administered in combination with systemic corticosteroids to induce a prolonged remission period or 



































































[18, 55]. In a recent randomized, observer-blind, parallel group, controlled trial involving 112 patients with  cutaneous 
PG, similar remission rates were reported between groups treated with cyclosporine (4 mg/kg/day) and prednisolone 
(0.75 mg/kg/day) suggesting that the treatment decision should be based on patient profile and possible adverse effects 
[55]. Monoclonal antibodies such as Infliximab (anti-TNF-α) and Adalimumab have been suggested as secondary 
lines of treatment for refractory multifocal disseminated lesions or in cases of multiple organ involvement [13, 28, 
56]. In patients diagnosed with inflammatory bowel disease, Infliximab is often the therapeutic drug of choice [28, 
57, 58]. Some reports of treatment with thalidomide and colchicine demonstrate variable responses [5, 17, 19, 59]. 
 In addition to systemic corticosteroids, local ulcer care is suggested to enhance patient comfort and prevent 
secondary microbial or fungal infections. Chlorhexidine 0.12 % mouth rinse can be used to achieve this in oral PG 
[21, 24, 31]. Topical clobetasol propionate (Dermovate 0.05%) or Tacrolimus (Protopic 0.1% or 0.03%) can be used 
as adjuvants to systemic therapy to relieve symptoms [9, 23]. Surgical debridement without concomitant medically 
induced immunosuppression or pre-operative corticosteroids should be avoided as surgery has been demonstrated to 
exacerbate cutaneous PG [3, 36, 51, 56, 60]. Similarly, in oral PG, Yco et al reported that a PG ulcer spread to the 
adjacent alveolar ridge after a biopsy was undertaken [10]. Recurrence of PG is always possible as 10% (2/20) of 
cases with oral involvement have shown relapses over a period of time without appropriate maintenance therapy [22, 
30]. Low dosage corticosteroids with or without Dapsone can be used as such [14, 29, 34, 61].  
 
Conclusion  
PG is an uncommon dermatological condition with very rare oral involvement. Few reports of oral lesions 
have been documented since the first description of PG by Brunsfing et al in 1930 [62]. Considering the possible 
morbidity associated with this disease, recognition and early diagnosis is of great importance. Exclusion of entities 
with a similar clinical appearance is essential. Clinicians must consider PG as a possible diagnosis for persistent and 
recurrent oral ulcers of unknown etiology, especially in patients with persistent skin ulcers, an underlying systemic 
disease known to be associated with PG, and/or when a lesion worsens following biopsy or antibiotic therapy. To 
guide the clinician in the diagnosis of oral PG lesions, we propose a set of diagnostic criteria based on the important 
clinico-pathological features gathered from the reported cases (Table 4).  
Standardized treatment protocols for mucosal lesions are still lacking and there is no scientific evidence to 



































































interventions must be considered as possible triggers of oral lesions in patients diagnosed with cutaneous PG. 
Therefore, dentists must act with precaution when considering surgery on a patient previously diagnosed with 
cutaneous PG as research evaluating the risks of inducing oral lesions and the therapeutic modalities to treat such 
iatrogenically induced lesions are non-existent. Early diagnosis, proper management and consistent follow-up are 
essential due to the morbidity associated with these lesions and the significant risk of relapse reported in up to 30 % 
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Figure Captions  
 
Fig. 1 This 67-year-old white make presented a thin leukoplakic lesion on the posterior dorsal tongue.  His medical 
history included hypertension, diabetes and dyslipidemia, for which he took rovustatin, metformin and olmesartan. 
He reported a 20 pack-year smoking history, having quit smoking 2-months prior, and consumed 6 beers/week for the 
last 40 years. The lesion was biopsied and diagnosed as hyperkeratosis with focal mild epithelial dysplasia and no 
evidence of candidiasis. At the one-week post-op examination, he presented normal healing of the biopsy site. One 
month later, he presented to the emergency dental clinic complaining of tongue discomfort. A large necrotic ulcer at 
the site of the biopsy was noted (picture). There was no purulence or submandibular lymphadenopathy. A second 
biopsy of the border of the ulcer was signed out as a non-specific ulcer. The patient was prescribed Chlorhexidine 
0.12% rinses BID and clindamycin 500mg TID x 14 days. The lesion healed gradually over the next two months. 
Shortly after, he was diagnosed with primary lung cancer (the patient did not know which type). 
 




Table 1 Published cases of oral involvement in patients with PG 
Table 2 Epidemiological data  
Table 3 Differential diagnosis of oral PG41-45 














































































Fig 1 Click here to download Figure Fig. 1.tiff 
From:  Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-
Analyses: The PRISMA Statement. PLoS Med 6(6): e1000097. doi:10.1371/journal.pmed1000097 
 
For more information, visit www.prisma-statement.org. 
 
PRISMA 2009 Flow Diagram 
 
Records identified through database 
searching 































Additional records identified 
through other sources 
(n = 13) 
Records after duplicates removed 
(n = 659) 
Records screened 
(n = 659) 
Records excluded 
(n = 630) 
Full-text articles assessed 
for eligibility 
(n = 30) 
Full-text articles excluded, 
with reasons: 
 
Insufficient clinical data to 
support PG diagnosis for 
oral lesions (n = 9 : Basu 
et al, Lazarus et al, 
Margoles et al (2nd case), 
Drinda, Tsuboi, 
O’Loughlin, Siddiqui et al, 
Marzano et al, Baloch et 
al, Kaomongkolgit et al) 
 
Absence of patient record 
(n = 1 : Basu et al) 
 
Studies included in 
qualitative synthesis 
(n = 20) 





Oral Lesions and  
Other PG Manifestations 
Oral Biopsy 
Successful treatment 
modalities and Follow-up 






Deep irregular ulceration (4 x 4.5 cm) on the L side of the 
palate and maxillary alveolar ridge. Base of the lesion friable 
and granular. Lesion is firm but noninvasive. 
Other PG Manifestations: None 
Non-specific inflammation. 
No bacterial infection. 
Prednisone PO 10 mg TID 
 
Lesion healed within 6 mo  
Philpott J et al, 1966 
M/83 RA 
Diabetes mellitus 
1-week sudden onset of painful subcutaneous nodules on the 
tongue, with rapid development of necrosis. 
Other PG Manifestations: Similar lesions affecting the R 
arm, L foot and scrotum. R forearm ulcer measured up to 12 
cm with complete loss of subcutaneous tissue. Similar lesions 3 
mo prior that healed with local treatment (gold leaf). 
None  Sodium Cephalothin 1 g QID x 
10 days. Followed by 
Prednisone PO 60 mg die. 
 
No new lesions appeared with 
prednisone therapy. Ulcer of R 
forearm subsequently grafted 
with good results. Free of 
lesions for 10 mo while on 
maintenance dose of 
corticosteroids. 
Yusuf H & Ead RD, 1985 
M/61  Arthritis 
Diverticular disease 
Exuberant granulomatous lesion on the R side of the tongue, 3 
cm in diameter and painful. Increased in size, along with hand 
ulcer, when initially treated with antibiotics. 
Other PG Manifestations: 3cm ulcer with blue undermined 
borders on dorsum of R hand. Similar episode 7 yrs prior on 
abdominal wall, accompanied by gingival and tongue ulcers. 
None  Prednisolone PO 100 mg die + 
Adrenocorticotropic hormone 
IM 80 mg 
 
Tongue and hand lesions 
improved after 1 week. Tongue 
lesion clearing completely in 4 
wks.  
Snyder RA, 1986 
F/29 None Pustular eruption of oral mucosa evolving into ulcers 
Other PG Manifestations: Other PG lesions involving cheek, 
periauricular area, antihelix of ear (large undermined ulcer), 
chin, R lower leg (2 x 2 cm ulceration with undermined edges). 
Fever. 
None  Methylprednisolone IV 50 mg 
BID + Dapsone PO 100 mg die 
+ Intralesional injection of 
Triamcinolone 20 mg/mL/week 
 
Complete healing of ulcers after 
6 wks of prednisolone and 
dapsone therapy. Free of 
disease for 4 yrs without 
treatment. 





Oral Lesions and  
Other PG Manifestations 
Oral Biopsy 
Successful treatment 
modalities and Follow-up 
Kennedy KS et al, 1987 









2 x 1 cm ulcer on the L lateral mid tongue present for 6 wks. 
Irregular borders, raised, pale, infiltrated edges. Center of the 
ulcer: light tan color. Tender to palpation. 
Other PG Manifestations: Shallow, crusted 5 mm ulcers of 
the nose, ear tragus and lobe, unrelated to trauma, present for 6 
wks without evidence of healing. Voice hoarseness caused by 
small vocal cord ulcers. 6 cm erythematous shallow ulcer of R 
wrist. R dorsal foot showed 8 cm shallow violaceous ulcer with 
raised borders. All ulcers were tender to palpation. 
Mucosal ulceration and necrosis with 
severe inflammatory infiltrate 
comprised of neutrophils with a few 
lymphocytes extending to the skeletal 
muscle. Absence of granulomas and 
vasculitis. 
Cefazolin IV x 5 days + 
Methylprednisolone pulse 
therapy 1 g/day x 5 days. 
Maintenance therapy: 
Prednisone PO 30 mg every 
other day 
 
Healing after 5 days of 
Cefazolin and 
methylprednisolone therapy.  
Patient lost to follow-up. 
Yco MS et al, 1988 
M/62 PV 
Erythema migrans 
Vascular-appearing tumor on the mid hard palate, tender and 
firm. Present for 5 days, measured 1 x 1 cm initially. 
Lesion spread after biopsy to involve entire hard palate and 
lingual alveolar ridge. 
Other PG Manifestations: PG of the leg 2 yrs previously. 
Eventually developed PG of the left postauricular crease and 
lateral neck. 
Necrosis, vasculitis and inflammation 
consistent with but not pathognomonic 
for PG 
Symptomatic therapy: kaolin, 
pectin, lidocaine and Benadryl 
mouthwash 
 
2 wks after biopsy, the lesion 
steadily healed and the palatal 
mucosa eventually returned to 
normal. 
Buckley C et al, 1990 
M/35 None Recurrent, severe painful pharyngeal ulceration extending to 
the soft palate and tongue 
Other PG Manifestations: Recurrent oral ulcerations were 
followed by typical PG ulcers on the shins and hands. 
Ulcer surrounded by dense mixed 
inflammatory infiltrate and a vascular 
bed. 
Prednisolone 60-80 mg die 
controlled the disease for 4 
years. Then, complete remission 
with thalidomide 100 mg die for 
2 years – withdrawn due to the 
development of peripheral 
neuropathy. Maintenance 




Complete clearance of 
cutaneous lesions with 
maintenance therapy. 






Oral Lesions and  
Other PG Manifestations 
Oral Biopsy 
Successful treatment 
modalities and Follow-up 
Bertram-Callens A et al, 1991 
M/62 PV Multiple ulcerations with central necrosis and hemorrhage on 
the dorsal surface of the tongue (5 cm), the lips, gingiva and the 
palate (< 1 cm). The lesion on the tongue had a hyperplastic 
and exophytic aspect. 
Other PG Manifestations: PG affecting the R leg, dorsum of 
the foot, and eyes (conjunctivitis, anterior uveitis, corneal ulcer 
and abscess) 
None.  
Yeast culture of the lingual ulcer 
showed Candida pseudotropicalis 
(carrier state). 
Methylprednisolone 80 mg: 2 
IM injections 
 
Complete healing of cutaneous, 
buccal and ocular ulcers within 
1 week.  
 




1st episode: tender swelling, erosions and crusts on lower lip.  
2nd episode: Necrotic ulcer of entire lower lip  
Other PG Manifestations: None 
Ulcerated epithelium with central 
fibrinoid necrosis of the corium, 
chronic inflammatory cell infiltrate 
including a few neutrophils. An 
infective etiology was excluded. 
Prednisolone PO 80 mg die 
 
Rapid healing of the lesion. The 
dose was gradually reduced. 
Setterfield J et al, 2001 
M/54 IgA 
paraproteinaemia 
Well-defined necrotic oropharyngeal ulceration (5 x 4 cm) and 
ulcers on the R commissure, lateral borders of the tongue and R 
buccal mucosa. 
Other PG Manifestations: Concurrent ulceration of the L 
lower limb. PG ulceration of the R lower limb 4 yrs previously. 
Several oral biopsies were performed. 
Each demonstrated a superficial 
neutrophilic infiltrate, mixed chronic 
inflammatory cell infiltrate in the 
corium. No evidence of vasculitis. 
Pulsed IV therapy administered 
monthly (6 courses) with 
Methylprednisolone 1 g daily 
for 3 days + Cyclophosphamide 
500 mg for 1 day 
 
Complete healing of the oral 
ulceration.  
Hernandez-Martin A et al, 2003 
F/84 Refractory anemia 
with ringed sidero-
blasts, MGUS 




Extensive ulceration of 3-mo duration involving the R soft and 
hard palate and the R tonsil 
Other PG Manifestations: None 
 
Dense neutrophilic infiltrate in the 
corium. Dense mixed inflammatory cell 
infiltrate in the deeper portion of the 
mucosa. No evidence of vasculitis. PAS 
and Gram stains negative. 
 
Corticosteroids PO 1.5 mg/kg 
die 
 
Resolution of the oral ulcer 





Oral Lesions and  
Other PG Manifestations 
Oral Biopsy 
Successful treatment 
modalities and Follow-up 
Park HJ et al, 2003 
M/8 None Painful enlarging ulcer (1 x 1 cm) on L lateral tongue covered 
by yellowish debris. Present for 1 mo. 
Other PG Manifestations: None 
Ulceration with necrosis extending to 
the skeletal muscle with a dense 
inflammatory cell infiltrate comprised 
of neutrophils and eosinophils. No 
evidence of vasculitis. Tissue culture 
negative for fungus but positive for S. 
viridans and F. oryzihabitans. 




Healing within 6 mo with 
scarring of tongue. No 
recurrences one year after 
cessation of Cyclosporine A 




Deep ulcers with erythematous borders and central necrosis on 
the R buccal commissure and tongue. Multiple pharyngeal 
ulcers. 
Other PG Manifestations: History of pustules and painful 
ulcers of perianal area since the age of 22. 
2 mo previously, she presented with extensive PG ulcerations 
involving axillary, perianal and popliteal areas. 
Conjunctivitis. Nasal septal perforation. 
Neutrophilic infiltrate in the epithelium 
and submucosa with presence of 
lymphocytes and histiocytes. Absence 
of vasculitis, angiocentric cellular 
infiltrate or granulomas. Lymphocytes 
were CD45RO+, CD3+, CD20-, CD56-
. EBER negative. C-ANCA negative. 
Prednisolone PO 20 mg die. 
Maintenance therapy: 
Prednisolone PO 7.5 mg die 
 
Partial regression of oral ulcers 
with Prednisolone 20 mg die.  
Pharyngeal and perianal ulcers 
persist with maintenance 
therapy. 
Paramkusam G et al, 2010 
F/42 None Solitary elliptical 4 x 2 cm ulcer (preceded by a papule) with 
undermined erythematous borders on the anterior hard palate. 
Necrotic bone present at the bottom of the ulcer. Pus discharge. 
Tenderness upon palpation. Bone loss surrounding teeth in the 
area. Second lesion on left retromolar area two weeks after start 
of treatment 
Other PG Manifestations: Multiple recurrent PG ulcers of the 
lower and upper extremities and the abdomen for the past 3 yrs. 
Healing with cribriform scarring. 
Central necrosis with neutrophilic 
infiltration, surrounded by dense 
collections of lymphocytes and plasma 
cells. Proliferating capillaries. Presence 
of fragments of bones with debris. 
Prednisolone PO 30 mg die + 
Dapsone + Metronidazole 
ointment TID + Chlorhexidine 
0.12 % mouth wash TID + 
Debridement of the lesion 
 
Both the palatal and retromolar 
lesions healed within 6 wks.  






Multiple ~1 cm necrotic ulcers with violaceous borders and flat 
violaceous papules on the tip of the tongue and the lower labial 
mucosa. 
Other PG Manifestations: Abdominal SC injections of 
Enoxaparin was followed by the appearance of a periumbilical 
crater-like necrotic ulcer surrounded by erythema. Surgical 
debridement of the abdominal ulceration was followed by 
lesional enlargement. Arthritis of the ankle, mesenteric 
panniculitis and interstitial pulmonary infiltrate. 
Sheets of neutrophils within the 
epithelium and corium. No evidence of 
vasculitis or neoplasia. 
Methylprednisolone IV 1500 
mg (bolus) followed by 
Prednisone 1 mg/kg die 
 
Oral ulcers healed within 3 wks. 






Oral Lesions and  
Other PG Manifestations 
Oral Biopsy 
Successful treatment 
modalities and Follow-up 
Chariatte N et al, 2011 
M/82 UC Ulcerated tumefaction on the R buccal mucosa (4 x 1 cm) with 
necrosis in the anterior portion. 
Other PG Manifestations: A few days later, inflammatory 
papules, which eventually formed central ulcers, formed on the 
arms, axillae, thorax and back.  
 
Recurrence of skin lesions 4 yrs later. 
Deep ulcer with its base extending to 
the muscular layer, covered by a thick 
layer of reticulated fibrin. Mixed 
inflammatory cell infiltrate 
(neutrophils, eosinophils, lymphocytes 
and histiocytes). At the margins, the 
mucosa is hyperplastic in there is 
presence of pus. No evidence of 
vasculitis. Histiocytes and plasma cells 
in the lateral deeper portions. 
Prednisone 50 mg die with 
topical Protopic 0.1% 
application (with sterile gauze) 
 
Favorable evolution of 
cutaneous lesions. Recurrences 
of PG in the following years 
when corticosteroids were 
ceased. 





Deep ulcers of the tongue and buccal mucosa. Tongue ulcer 
measures 3 cm in diameter, with irregular borders, rolled 
erythematous margins and a granular erythematous ulcer bed. 
Other PG Manifestations: 6-week history of widespread 
necrotizing cutaneous ulceration painful deep ulceration 
involving both breasts, abdomen, perianal skin and feet 
None. 
 
Cutaneous biopsies lead to a diagnosis 
of PG with oral involvement. 
Pulsed IV Methylprednisolone 
1 g + Broad spectrum 
antibiotics + Prednisolone 60 
mg die resulted in a dramatic 
reduction in pain in 48 h. MMF 
2 g die was then introduced. 
 
Mucosal and cutaneous ulcers 
healed within 5 wks of MMF 
treatment.  
Curi MM et al, 2013 
M/58 UC Extensive (3 x 2 cm) ulceration, covered by a yellow 
pseudomembrane with a peripheral erythematous halo, on the L 
tonsillar pillar and soft palate. Superficial ulcer on the R side of 
the tongue. 
Other PG Manifestations: Multiple ulcerations of the trunk, 
limbs, face and eyelid, diagnosed clinically and 
histopathologically as PG. 
None Oral lesions managed with 
Chlorhexidine 0.12% mouth-
wash and topical corticosteroids 
Prednisolone PO 40 mg die + 
Mesalazine 800 mg die, 
Oxacillin 2 g die 
 
Rapid and complete resolution 
of the mucocutaneous lesions 





Oral Lesions and  
Other PG Manifestations 
Oral Biopsy 
Successful treatment 
modalities and Follow-up 




Recurrent, painful, ulcerative skin and mouth lesions. Fluid-
filled bullae that ruptured forming ulcers which gradually 
increased in size on the lip vermilion, tongue and labial 
mucosa.  
Lip swelling and crusting. 
Other PG Manifestations: PG lesions involving the lower and 
upper limbs. 
Extensive neutrophilic infiltration, 
hemorrhage and mononuclear cells. 
Neutrophils around and within the 
vascular walls.  Leukocytoclasia but no 
evidence of vasculitis. No tissue 
immunofluorescence was done. 
IV Vancomycin 1 g die + 
Prednisolone 40 mg die + local 
wound care for one week.  
Cyclosporine 150 mg die + 
Dapsone 100 mg 
 
Progression of disease halted 
after one week of treatment. 
Rapid and good response with 
addition of Cyclosporine and 
Dapsone 
Zampelli VA et al, 2015 
F/36 UC Shallow round ulcers with a central fibrinous membrane, 
bordered by an erythematous halo on the R lateral tongue and 
the L buccal mucosa 
Other PG Manifestations: Skin ulcerations compatible with 
PG involving the axillary and submammary areas, the mons 
pubis, trunk, face, outer ear and extremities. 
None Prednisolone 1 mg/kg die + 
antibiotics + Mesalazine for 10 
days, without improvement of 
lesions. Infliximab infusions 
were started at 5 mg/kg on 
weeks 0, 2 and 6 
 
Lesions showed fast healing 
after initiation of infliximab. 
F: female, M: male, NI: not indicated, L: left, R: right, wks: weeks, mo: months, yrs: years, IM: intramuscular, PO: per os, IV: intravenous, IBD: inflammatory bowel disease, RA: 
rheumatoid arthritis, UC: ulcerative colitis, PV: polycythemia vera, HBP: high blood pressure, MGUS: monoclonal gammopathy of unknown significance, MMF: Mycophenolate 
Mofetil 
 
 Number of cases reported (%) 
Sex (n=20) 
    Female 7 (35.0 %) 
    Male 13 (65.0 %) 
Age (n=20) 
    < 20 years 1 (5.0 %) 
    20-40 years 7 (35.0 %) 
    40-60 years 5 (25.0 %) 
    60-80 years 4 (20.0 %) 
    > 80 years 3 (15.0 %) 
Associated underlying disease (n=20) 
    No underlying condition 5 (25.0 %) 
    Inflammatory Bowel Disease 6 (30.0 %) 
Ulcerative Colitis : 4 (20.0 %) 
    IgA paraproteinemia 2 (10.0 %) 
    Polycythemia Rubra Vera 2 (10.0 %) 
    Rheumatoid Arthritis 2 (10.0 %) 
    Leukemia 1 (5.0 %) 
    Paroxysmal nocturnal  
    haemoglobinuria     
1 (5.0 %) 
    Diverticular disease  1 (5.0 %) 
Oral Pathergy (Trauma or surgery) (n=20) 
    Yes 1 (5.0 %) 
    No 19 (85.0 %) 
Sites affected (n=34) 
    Tongue 13 (38.2 %) 
    Buccal mucosa 6 (17.6 %) 
    Soft palate 4 (11.8 %) 
    Hard palate 3 (8.8 %) 
    Oropharynx 2 (5.9 %) 
    Lip 2 (5.9 %) 
    Commissure 2 (5.9 %) 
    Retromolar area 1 (2.9 %) 
    Gingiva 1 (2.9 %) 
 
Table 2 Click here to download Table Table 2 - Epidemiological
data.docx




Clinical appearance Histopathologic features  Additional diagnostic workup 
Mucosal 
tuberculosis  
Chronic ulceration and/or granular 
swelling of the mucosa 
Palpable cervical lymph nodes 
Necrotizing granulomatous inflammation 
Langhans giant cells 
Mycobacterial organisms revealed by Acid-






Linear vestibular ulcers  
Cobblestone appearance of the mucosa / 
mucosal tags 









with polyangiitis  
Strawberry gingivitis 
Oral ulcerations – later stage 
Leukocytoclastic vasculitis, granulomatous 
inflammation 
 
Elevated antineutrophil cytoplasmic 




Irregular endo- or exophytic indurated, 
red, white and/or ulcerated mass 
Often painless in early stages 
Sites of predilection: latero-ventral 
tongue, floor of mouth and soft palate. 
Loco-regional lymphadenopathy 
Invasive malignant squamous cells arising 
from overlying dysplastic oral epithelium 
 
Chest X-ray 





Rapid onset of swelling and pain of the 
lateral posterior hard palate, followed by 
the appearance of a crater-like ulceration.  
Regression of the lesion without 
treatment. 
Necrosis of mucous acinar cells with 
preservation of the lobular architecture of 




T-cell lymphoma Intraoral involvement is rare and most 
often preceded by cutaneous lesions. 
Erythematous indurated plaques/nodules 
that are ulcerated. Tongue, palate and 
gingiva are most frequently affected. 
Atypical lymphocytic cells 
Pautrier micro-abscesses 
Extensive, dense infiltrate comprised of 
atypical lymphocytes. 
Lymphocytic population is CD4+ 






Deep, chronic ulceration with elevated 
borders 
Polymorphic inflammatory infiltrate with 
abundant eosinophils in the superficial 
mucosa and muscle layer 
Atypical large mononuclear cells (some 
cases) 
 
Tertiary syphilis  Syphilitic gumma: Nodular, indurated or 
ulcerated lesion capable of causing 
Peripheral pseudoepitheliomatous 
hyperplasia with granulomatous 
inflammation and multinucleated giant cells 
Serologic screening tests : VDRL and RPR 
Table 3 Click here to download Table Table 3 - Differential diagnosis of oral PG -
Revised_GM.docx
extensive tissue destruction. Palate or 
tongue are most frequently affected. 
Neutropenic 
ulcers 
Ulcerations usually involving the gingival 
mucosa with or without an erythematous 
border 
Non-specific ulceration Reduced number or 
absence of neutrophils 
 
Complete blood count 
Recurrent major 
aphthous ulcers 
Ulcerations on the nonkeratinized mucosa 
covered by a fibrino-purulent membrane 
and surrounded by an erythematous halo 
measuring more than 1cm in diameter. 
Very painful 
Heals with scarring within 3-6 weeks 
Mixed inflammatory cell infiltrate 
Central zone of ulceration 
 
Investigate nutritional deficiencies, IBD, 







Chronic ulcerations with variable 
presentations 
Granulomatous inflammation 
Identification of fungal organisms with 
special stains  
Tissue culture  
Investigate immune suppression 
  
Table 4. Proposed diagnostic criteria for oral PG lesions – point score system:  
A scoring of >3 points indicates disease  
 
Necessary criteria: 1 point 
Large (>1cm) chronic or recurrent oral ulcers with a granular appearance or 
undermined, rolled-out reddish-purple irregular margins 
 
Major criteria:  2 points each 
1. Presence or history of skin lesions diagnosed as PG OR diagnosis of PAPA or 
PASH syndromes 
2. Oral ulceration appears or progresses following minor surgical or traumatic 
event (pathergy effect) OR progresses following antibiotic therapy. 
 
Minor criteria: 1 point each 
1. Presence of a reddish-purple papule preceding the appearance of an oral 
ulcer. 
2. Oral biopsy shows non-specific chronic inflammation (infectious etiologies, 
vasculitidies, granulomatous inflammatory conditions and neoplastic 
processes ruled out).  
3. Presence of an underlying systemic disorder known to be associated with PG. 






Table 4 Click here to download Table Table 4 - Major minor diagnostic
criteria.docx
